title: Ovarian cancer: patterns of care in Victoria during 1993-1995.
abstract: OBJECTIVE
  To describe the management of and outcomes in patients with newly diagnosed ovarian cancer during 1993, 1994 and 1995 in Victoria.
  
  
  METHODS
  Retrospective cohort study conducted by surveying doctors involved in managing incident ovarian cancer cases identified from the population-based Victorian Cancer Registry. The survey was conducted in 1997 and the cohort was followed up until the end of 1999 to obtain at least four years of follow-up data on all patients.
  
  
  METHODS
  All women with invasive epithelial ovarian cancer diagnosed during 1993, 1994 and 1995.
  
  
  METHODS
  Reported management in terms of staging, treatment and survival.
  
  
  RESULTS
  Management details were obtained for 84.5% (562/665) of eligible patients. Median age at diagnosis was 66 years (range, 22-98 years). Surgery was the primary therapy in 77.2% of women (434/562). Only one in three women had adequate surgery, which was less likely to be performed by general gynaecologists and general surgeons than gynaecological oncologists (21.3% [35/164] v 13.3% [8/60] v 52% [105/202]). After surgery 78.6% of women (341/434) received chemotherapy, usually with platinum-based regimens. The overall five-year relative survival was 46% for women treated surgically; poor survival was related to increasing age, later tumour stage, presence of ascites, residual disease > 2 cm and poorer histological differentiation of the tumour.
  
  
  CONCLUSIONS
  For optimal care a preoperative carcinoma antigen (CA)-125 assay, chest x-ray and pelvic ultrasound should be performed, and early referral to a multi-disciplinary unit for definitive surgery is advised. Every effort should be made to adequately stage or debulk the tumour. Women with high-risk early-stage and advanced disease should be considered for platinum-based chemotherapy.
authors.affiliation: Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
authors.forename: Marisa
authors.initials: M
authors.lastname: Grossi
authors.forename: Michael A
authors.initials: MA
authors.lastname: Quinn
authors.forename: Vicky J
authors.initials: VJ
authors.lastname: Thursfield
authors.forename: Prudence A
authors.initials: PA
authors.lastname: Francis
authors.forename: Robert M
authors.initials: RM
authors.lastname: Rome
authors.forename: Robert S
authors.initials: RS
authors.lastname: Planner
authors.forename: Graham G
authors.initials: GG
authors.lastname: Giles
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D014739:Victoria
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate